PL2678006T3 - Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu - Google Patents

Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu

Info

Publication number
PL2678006T3
PL2678006T3 PL12706778T PL12706778T PL2678006T3 PL 2678006 T3 PL2678006 T3 PL 2678006T3 PL 12706778 T PL12706778 T PL 12706778T PL 12706778 T PL12706778 T PL 12706778T PL 2678006 T3 PL2678006 T3 PL 2678006T3
Authority
PL
Poland
Prior art keywords
packaging
active substance
pharmaceutical preparations
solid pharmaceutical
preparations containing
Prior art date
Application number
PL12706778T
Other languages
English (en)
Inventor
Thomas Zimmeck
Henning Ueck
Julia Gehricke
Original Assignee
G Pohl Boskamp Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by G Pohl Boskamp Gmbh & Co Kg filed Critical G Pohl Boskamp Gmbh & Co Kg
Publication of PL2678006T3 publication Critical patent/PL2678006T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00Containers, packaging elements or packages, specially adapted for particular articles or materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A61J1/035Blister-type containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12706778T 2011-02-25 2012-02-24 Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu PL2678006T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011012491 2011-02-25
PCT/EP2012/000802 WO2012113563A1 (en) 2011-02-25 2012-02-24 Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate
EP12706778.3A EP2678006B1 (en) 2011-02-25 2012-02-24 Packaging of solid pharmaceutical preparations containing the active substance glyceryl trinitrate

Publications (1)

Publication Number Publication Date
PL2678006T3 true PL2678006T3 (pl) 2016-06-30

Family

ID=45787158

Family Applications (2)

Application Number Title Priority Date Filing Date
PL12707232T PL2678000T3 (pl) 2011-02-25 2012-02-24 Stabilizowane granulaty zawierające triazotan glicerolu
PL12706778T PL2678006T3 (pl) 2011-02-25 2012-02-24 Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL12707232T PL2678000T3 (pl) 2011-02-25 2012-02-24 Stabilizowane granulaty zawierające triazotan glicerolu

Country Status (7)

Country Link
US (4) US20130327676A1 (pl)
EP (3) EP2678000B1 (pl)
AU (2) AU2012219926B2 (pl)
CA (2) CA2827714A1 (pl)
ES (2) ES2565632T3 (pl)
PL (2) PL2678000T3 (pl)
WO (2) WO2012113563A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668947B1 (en) * 2012-05-31 2016-11-30 G. Pohl-Boskamp GmbH & Co. KG Induction of arteriogenesis with a nitric oxide-donor such as nitroglycerin
WO2019009927A1 (en) * 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc MIXTURE COMPOSITIONS FOR ORAL ADMINISTRATION AS POWDER AND / OR SUSPENSION WITH RAPID DISSOLUTION

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (pl) 1962-05-24
US3432593A (en) * 1963-09-18 1969-03-11 Key Pharm Inc Delayed and sustained release type pharmaceutical preparation
GB1205019A (en) * 1966-12-07 1970-09-09 Sterwin Ag Improvements in or relating to oral dosage forms
US3789119A (en) * 1971-06-01 1974-01-29 Parke Davis & Co Stabilized molded sublingual nitroglycerin tablets
JPS599539B2 (ja) 1979-11-13 1984-03-03 日本化薬株式会社 ニトログリセリン水溶液及びその製造法
CA1163195A (en) 1980-06-26 1984-03-06 Alec D. Keith Polymeric diffusion matrix containing a vasodilator
US4542013A (en) * 1981-07-08 1985-09-17 Key Pharmaceuticals, Inc. Trinitroglycerol sustained release vehicles and preparation therefrom
DE3246081A1 (de) 1982-12-13 1984-06-14 G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt Nitroglycerin-spray
EP0341264A4 (en) 1987-01-23 1991-03-20 The General Hospital Corporation Atriopeptins, guanylate cyclase activators, and phosphodiesterase inhibitors as treatment for glaucoma, hydrocephalus and cerebral edema (cranial fluid volume dysfunction)
JPH0645538B2 (ja) 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
HU199678B (en) 1988-07-08 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing aerosols containing nitroglicerol
DE4007705C1 (pl) 1990-03-10 1991-09-26 G. Pohl-Boskamp Gmbh & Co. Chemisch-Pharmazeutische Fabrik, 2214 Hohenlockstedt, De
DE4018919C2 (de) 1990-06-13 1994-08-25 Sanol Arznei Schwarz Gmbh Nitroglycerin-Spray
US5370862A (en) 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
DE4026072A1 (de) 1990-08-17 1992-02-20 Sanol Arznei Schwarz Gmbh Nitroglycerinhaltiger, hydrophiler, waessriger pumpspray
DE4038203A1 (de) 1990-11-30 1992-06-04 Kali Chemie Pharma Gmbh Pharmazeutische spray-zubereitungen mit coronaraktiven wirkstoffen
US5698589A (en) 1993-06-01 1997-12-16 International Medical Innovations, Inc. Water-based topical cream containing nitroglycerin and method of preparation and use thereof
US5869082A (en) 1996-04-12 1999-02-09 Flemington Pharmaceutical Corp. Buccal, non-polar spray for nitroglycerin
US20010044584A1 (en) 1997-08-28 2001-11-22 Kensey Kenneth R. In vivo delivery methods and compositions
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
EP1019039B1 (en) * 1997-10-03 2001-12-05 Warner-Lambert Company Compressed nitroglycerin tablet and its method of manufacture
US6796966B2 (en) 1997-10-15 2004-09-28 Jeffrey E. Thomas Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
WO1999038472A2 (en) 1998-01-28 1999-08-05 Seatrace Pharmaceuticals Inc Topical vasodilatory gel composition and methods of use and production
US5989529A (en) 1998-11-20 1999-11-23 Schering-Plough Healthcare Products, Inc. Substantive topical composition
IT1303793B1 (it) * 1998-11-27 2001-02-23 Promefarm S R L "composizione farmaceutica comprendente un composto organico donatoredi ossido nitrico (no)"
US6962691B1 (en) 1999-05-20 2005-11-08 U & I Pharmaceuticals Ltd. Topical spray compositions
RU2174838C2 (ru) 1999-11-04 2001-10-20 Ивановская государственная медицинская академия Способ лечения тяжелого бронхообструктивного синдрома у детей раннего возраста
AU2727701A (en) 1999-12-15 2001-06-25 Cellegy Pharmaceuticals, Inc. Nitroglycerin ointment for treatment of pain associated with anal disease
US6443307B1 (en) * 2000-01-25 2002-09-03 Michael D. Burridge Medication dispenser with an internal ejector
WO2001068062A2 (en) * 2000-03-14 2001-09-20 Noven Pharmaceuticals, Inc. Packaging materials for transdermal drug delivery systems
US6538033B2 (en) 2000-08-29 2003-03-25 Huntington Medical Research Institutes Nitric oxide donor compounds
CN1545421A (zh) 2001-06-22 2004-11-10 �Ʒ� 包含低溶解度和/或酸敏感的药物以及中和的酸性聚合物的药物组合物
ES2276080T3 (es) * 2002-02-08 2007-06-16 THE PROCTER & GAMBLE COMPANY Bolsita a prueba de niños.
US20050095278A1 (en) 2003-01-14 2005-05-05 Viorel Nicolaescu Use of nitroglycerin to relieve nocturnal muscle cramps
US20040228883A1 (en) 2003-02-21 2004-11-18 Mitchell Karl Prepackaged aqueous pharmaceutical formulation for the treatment of cardiac conditions containing at least two different active agents and method of formulation
WO2005004989A2 (en) 2003-07-01 2005-01-20 Todd Maibach Film comprising therapeutic agents
US20070053966A1 (en) 2003-10-17 2007-03-08 Robert Ang Medicated orthopedic support structures for treatment of damaged musculoskeletal tissue
US7781226B2 (en) * 2004-02-27 2010-08-24 The Board Of Regents Of The University Of Texas System Particle on membrane assay system
EP1737482A4 (en) 2004-03-01 2010-09-15 Lumen Therapeutics Llc COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES
WO2005107461A2 (en) 2004-04-07 2005-11-17 The General Hospital Corporation Modulating lymphatic function
WO2007081206A1 (en) 2006-01-09 2007-07-19 Pantarhei Bioscience B.V. A method of treating an acute vascular disorder
EP2015632B1 (en) 2006-04-19 2015-12-02 Mist Pharmaceuticals, LLC Stable hydroalcoholic oral spray formulations and methods
US20080311162A1 (en) * 2007-05-16 2008-12-18 Olivia Darmuzey Solid form
CN101229148A (zh) * 2007-12-28 2008-07-30 天津医科大学 硝酸甘油口腔(舌下)崩解片的制剂及其制备方法
DE102008005484A1 (de) 2008-01-22 2009-07-23 Schaper, Wolfgang, Dr. Induktion und Förderung der Arteriogenese
EP2098249B1 (en) * 2008-03-05 2012-10-24 Rivopharm SA Nicorandil carriers with enhanced stability
US20100184870A1 (en) 2008-03-14 2010-07-22 Rolf Groteluschen Long-term stable pharmaceutical preparation containing the active ingredient glycerol trinitrate
DE202008007318U1 (de) 2008-03-14 2008-07-31 G. Pohl-Boskamp Gmbh & Co. Kg Langzeitstabile pharmazeutische Zubereitung mit dem Wirkstoff Glyceroltrinitrat
US20100016446A1 (en) 2008-07-21 2010-01-21 Sylvia Gonda Stable water-based topical pharmaceutical creams and methods of making and using same
CA2671029A1 (en) 2009-06-30 2010-12-30 James S. Baldassarre Methods of treating term and near-term neonates having hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension

Also Published As

Publication number Publication date
AU2012219926A1 (en) 2013-09-12
US20130331461A1 (en) 2013-12-12
EP2678000B1 (en) 2018-03-07
US20140370109A1 (en) 2014-12-18
CA2827714A1 (en) 2012-08-30
EP2678006A1 (en) 2014-01-01
ES2672261T3 (es) 2018-06-13
US9101592B2 (en) 2015-08-11
EP2678006B1 (en) 2015-12-30
US20130327676A1 (en) 2013-12-12
EP3354259A1 (en) 2018-08-01
AU2012219925B2 (en) 2017-02-23
CA2827716A1 (en) 2012-08-30
AU2012219926B2 (en) 2016-11-17
US9616023B2 (en) 2017-04-11
US20160000711A1 (en) 2016-01-07
AU2012219925A1 (en) 2013-10-03
CA2827716C (en) 2019-05-14
WO2012113563A1 (en) 2012-08-30
WO2012113564A1 (en) 2012-08-30
PL2678000T3 (pl) 2018-08-31
EP2678000A1 (en) 2014-01-01
ES2565632T3 (es) 2016-04-06

Similar Documents

Publication Publication Date Title
IL276012B (en) Pharmaceutical compositions comprising sorbitan esters
PH12014500449A1 (en) Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same
EP2938331A4 (en) LIPID PRECONCENTRATE WITH EXTENDED RELEASE OF A PHARMACOLOGICALLY ACTIVE CATIONIC SUBSTANCE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
ZA201306237B (en) Solid forms of a pharmaceutically active substance
IL238713A0 (en) Self-regulating active pharmaceutical ingredient release
IL226398B2 (en) Pharmaceutical formulations containing corticosteroids for administration on the skin
ZA201404035B (en) Microcapsule containing fungicidal active ingredient
EP2665471A2 (en) Controlled release oral pharmaceutical dosage forms comprising mgbg
ZA201400646B (en) Topical ophthalmological pharmaceutical composition containing regorafenib
IL236465A0 (en) Pharmaceutical composition for delayed release of active substances
PT2846839T (pt) Formulações para a administração de ingredientes ativos
HUE036784T2 (hu) Alisporivirt tartalmazó gyógyászati készítmények
HRP20160928T1 (hr) Farmaceutske kompozicije koje sadrže anakinra bez citrata
PL2678006T3 (pl) Pakowanie stałych preparatów farmaceutycznych zawierających substancję aktywną triazotan glicerolu
EP2882435B8 (en) Pharmaceutical formulations containing 3-(4-cinnamyl-L-piperazinyl) amino derivatives of 3-formylrifamycin S
HU1000444D0 (en) Process for the preparation of a pharmaceutical active ingredient
IL227651A0 (en) Pharmaceutical formulations for local introduction containing 220b
LT2704698T (lt) Vaisto forma, skirta aktyvių ingredientų kontroliuojamam atpalaidavimui
PL2585445T3 (pl) Polimorfy aktywnego składnika farmaceutycznego
SI2474529T1 (sl) Kristalne oblike aktivne farmacevtske učinkovine
ZA201403735B (en) Pharmaceutical formulations comprising atorvastatin and glimepiride
GB201216893D0 (en) Drug substance preparations, pharmaceutical compositions and dosage forms comprising s-(+)-flurbiprofen
ZA201105275B (en) Pharmaceutical formulation containing atorvastatin and method for the preparation thereof
HK1191857A (en) Pharmaceutical formulation for topical administration comprising b220
AU2011900419A0 (en) Cosmetic or pharmaceutical formulation